EA202090925A1 - Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1 - Google Patents

Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1

Info

Publication number
EA202090925A1
EA202090925A1 EA202090925A EA202090925A EA202090925A1 EA 202090925 A1 EA202090925 A1 EA 202090925A1 EA 202090925 A EA202090925 A EA 202090925A EA 202090925 A EA202090925 A EA 202090925A EA 202090925 A1 EA202090925 A1 EA 202090925A1
Authority
EA
Eurasian Patent Office
Prior art keywords
positive allosteric
allosteric modulators
heteroaryl compounds
muscarine receptor
formula
Prior art date
Application number
EA202090925A
Other languages
English (en)
Other versions
EA039781B1 (ru
Inventor
Рамакришна Нироджи
Абдул Рашид Мохаммед
Анил Карбхари Схинде
Сринивас Равелла
Ванаджа Миддекади
Винод Кумар Гоял
Прадип Джаяраджан
Саивишал Дарипелли
Венкатесварлу Джасти
Original Assignee
Сувен Лайф Сайенсиз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сувен Лайф Сайенсиз Лимитед filed Critical Сувен Лайф Сайенсиз Лимитед
Publication of EA202090925A1 publication Critical patent/EA202090925A1/ru
Publication of EA039781B1 publication Critical patent/EA039781B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Настоящее изобретение относится к соединениям формулы (I) или их изотопным формам, стереоизомерам, таутомерам или фармацевтически приемлемой соли (солям) в качестве позитивных аллостерических модуляторов мускаринового рецептора M1 (M1 PAMs). В настоящем изобретении описаны получение, фармацевтическая композиция и применение соединения формулы (I)
EA202090925A 2017-10-18 2018-10-17 Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1 EA039781B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741037090 2017-10-18
PCT/IB2018/058047 WO2019077517A1 (en) 2017-10-18 2018-10-17 HETEROARYL COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF M1 MUSCARINIC RECEPTOR

Publications (2)

Publication Number Publication Date
EA202090925A1 true EA202090925A1 (ru) 2020-07-13
EA039781B1 EA039781B1 (ru) 2022-03-14

Family

ID=64277732

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090925A EA039781B1 (ru) 2017-10-18 2018-10-17 Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1

Country Status (16)

Country Link
US (1) US11234979B2 (ru)
EP (1) EP3697790B1 (ru)
JP (1) JP7104783B2 (ru)
KR (1) KR102438588B1 (ru)
CN (1) CN111212840B (ru)
AU (1) AU2018353544B2 (ru)
BR (1) BR112020007606A2 (ru)
CA (1) CA3076757C (ru)
EA (1) EA039781B1 (ru)
IL (1) IL273748B (ru)
MA (1) MA50402A (ru)
MX (1) MX2020003832A (ru)
NZ (1) NZ764004A (ru)
SG (1) SG11202003284RA (ru)
WO (1) WO2019077517A1 (ru)
ZA (1) ZA202002034B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3078164C (en) 2017-10-27 2022-11-15 Suven Life Sciences Limited Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
MA53917A (fr) * 2018-10-17 2022-01-26 Suven Life Sciences Ltd Dérivés de pyrrolo-pyridazine en tant que modulateurs allostériques positifs du récepteur m1 muscarinique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062853A1 (en) 2009-11-20 2011-05-26 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide m1 receptor positive allosteric modulators
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
WO2015044072A1 (en) * 2013-09-27 2015-04-02 F. Hoffmann-La Roche Ag Indol and indazol derivatives
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2016172547A1 (en) 2015-04-24 2016-10-27 Vanderbilt University Substituted imidazopyridine and triazolopyridine analogs as positive allosteric modulators of muscarinic acetylcholine receptor m1
MD3303331T2 (ro) 2015-06-08 2019-05-31 Suven Life Sciences Ltd Modulatori alosterici pozitivi ai receptorilor muscarinici M1
CA2997956C (en) 2015-09-10 2019-10-29 Suven Life Sciences Limited Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
JP2021500323A (ja) 2021-01-07
JP7104783B2 (ja) 2022-07-21
EP3697790A1 (en) 2020-08-26
CN111212840B (zh) 2022-07-22
SG11202003284RA (en) 2020-05-28
CA3076757A1 (en) 2019-04-25
EA039781B1 (ru) 2022-03-14
WO2019077517A1 (en) 2019-04-25
EP3697790B1 (en) 2023-01-18
MX2020003832A (es) 2020-08-06
US20200237761A1 (en) 2020-07-30
IL273748B (en) 2022-06-01
KR20200069330A (ko) 2020-06-16
NZ764004A (en) 2023-03-31
CN111212840A (zh) 2020-05-29
AU2018353544A1 (en) 2020-04-16
BR112020007606A2 (pt) 2020-09-29
IL273748A (en) 2020-05-31
KR102438588B1 (ko) 2022-08-31
US11234979B2 (en) 2022-02-01
CA3076757C (en) 2022-10-11
ZA202002034B (en) 2021-05-26
AU2018353544B2 (en) 2020-09-17
MA50402A (fr) 2021-05-19

Similar Documents

Publication Publication Date Title
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
EA202090486A2 (ru) Соединения для лечения спинальной мышечной атрофии
PH12016501440A1 (en) Novel heterocyclic compounds
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201891179A1 (ru) N-замещенные индольные производные в качестве модуляторов pge2 рецепторов
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA202091256A1 (ru) Новые антагонисты рецептора брадикинина
EA201992679A1 (ru) N-замещенные индольные производные
EA201690888A1 (ru) Новые гетероциклические соединения
PH12018500377A1 (en) Novel annelated benzamides
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA201692298A1 (ru) Производные карбоксамидов
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
EA201501163A1 (ru) Модуляторы рецептора cxcr7
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
EA201692300A1 (ru) Производные карбоксамида
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
EA202090995A1 (ru) Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1
EA202090925A1 (ru) Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний